GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » InnoCan Pharma Corp (XCNQ:INNO) » Definitions » EPS (Diluted)

InnoCan Pharma (XCNQ:INNO) EPS (Diluted) : C$-0.02 (TTM As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is InnoCan Pharma EPS (Diluted)?

InnoCan Pharma's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was C$-0.00. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was C$-0.02.

InnoCan Pharma's EPS (Basic) for the three months ended in Dec. 2023 was C$-0.00. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was C$-0.02.

InnoCan Pharma's EPS without NRI for the three months ended in Dec. 2023 was C$-0.01. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was C$-0.02.

During the past 3 years, the average EPS without NRIGrowth Rate was 15.10% per year. During the past 5 years, the average EPS without NRI Growth Rate was -9.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 6 years, InnoCan Pharma's highest 3-Year average EPS without NRI Growth Rate was 15.10% per year. The lowest was -64.50% per year. And the median was 8.10% per year.


InnoCan Pharma EPS (Diluted) Historical Data

The historical data trend for InnoCan Pharma's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InnoCan Pharma EPS (Diluted) Chart

InnoCan Pharma Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EPS (Diluted)
Get a 7-Day Free Trial -0.04 -0.08 -0.06 -0.02 -0.02

InnoCan Pharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 -0.01 - -0.01 -

Competitive Comparison of InnoCan Pharma's EPS (Diluted)

For the Drug Manufacturers - Specialty & Generic subindustry, InnoCan Pharma's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


InnoCan Pharma's PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, InnoCan Pharma's PE Ratio distribution charts can be found below:

* The bar in red indicates where InnoCan Pharma's PE Ratio falls into.



InnoCan Pharma EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

InnoCan Pharma's Diluted EPS for the fiscal year that ended in Dec. 2023 is calculated as

Diluted EPS (A: Dec. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-6.306-0)/257.004
=-0.02

InnoCan Pharma's Diluted EPS for the quarter that ended in Dec. 2023 is calculated as

Diluted EPS (Q: Dec. 2023 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-1.185-0)/267.065
=-0.00

EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


InnoCan Pharma  (XCNQ:INNO) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


InnoCan Pharma EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of InnoCan Pharma's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


InnoCan Pharma (XCNQ:INNO) Business Description

Traded in Other Exchanges
Address
1015, 926 - 5 Avenue SW, Calgary, AB, CAN, T2P 0N7
InnoCan Pharma Corp is a pharmaceutical tech company that focuses on the development of several drug delivery platforms combining cannabidiol with other pharmaceutical ingredients as well as the development and sale of CBD-integrated pharmaceuticals. Geographically, it derives a majority of its revenue from the United States.

InnoCan Pharma (XCNQ:INNO) Headlines

From GuruFocus

President of Innocap, Inc. is in Singapore

By GlobeNewswire GlobeNewswire 05-03-2018

Innocap, Inc.'s Current Activities

By Marketwired Marketwired 05-24-2018

President of Innocap, Inc. is in Singapore

By Marketwired Marketwired 05-03-2018

Innocap, Inc. Year End Message To Shareholders

By PRNewswire PRNewswire 12-14-2020